Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $37.67

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $37.67.

A number of equities research analysts have issued reports on DAWN shares. Needham & Company LLC reissued a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, June 19th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, June 20th. JPMorgan Chase & Co. lifted their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, May 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th.

Insider Buying and Selling

In related news, CEO Jeremy Bender sold 70,051 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the sale, the chief executive officer now owns 651,762 shares of the company’s stock, valued at $11,653,504.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Jeremy Bender sold 70,051 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the sale, the chief executive officer now owns 651,762 shares of the company’s stock, valued at $11,653,504.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Saira Ramasastry sold 10,000 shares of the business’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $13.19, for a total transaction of $131,900.00. Following the sale, the director now directly owns 40,485 shares in the company, valued at approximately $533,997.15. The disclosure for this sale can be found here. Insiders have sold 185,534 shares of company stock valued at $3,207,830 over the last quarter. Corporate insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Quintet Private Bank Europe S.A. raised its holdings in Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after buying an additional 1,000 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Day One Biopharmaceuticals by 8.2% during the fourth quarter. Arizona State Retirement System now owns 13,373 shares of the company’s stock valued at $195,000 after purchasing an additional 1,010 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Day One Biopharmaceuticals by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after purchasing an additional 1,445 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Day One Biopharmaceuticals by 9.1% during the first quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after purchasing an additional 1,447 shares during the last quarter. Finally, Alps Advisors Inc. raised its holdings in shares of Day One Biopharmaceuticals by 2.5% during the third quarter. Alps Advisors Inc. now owns 64,153 shares of the company’s stock valued at $787,000 after purchasing an additional 1,592 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Stock Up 0.3 %

Shares of Day One Biopharmaceuticals stock opened at $13.50 on Monday. The firm has a market cap of $1.18 billion, a PE ratio of -5.38 and a beta of -1.51. Day One Biopharmaceuticals has a 12-month low of $9.67 and a 12-month high of $18.07. The company’s fifty day simple moving average is $14.43 and its two-hundred day simple moving average is $14.75.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). As a group, sell-side analysts expect that Day One Biopharmaceuticals will post -2.69 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.